<DOC>
	<DOCNO>NCT03100344</DOCNO>
	<brief_summary>The aim study assess efficacy multiple subcutaneous dose nemolizumab administrate concomitantly Topical Corticosteroids , moderate severe atopic dermatitis subject severe pruritus adequately control topical treatment .</brief_summary>
	<brief_title>Dose-ranging Study Nemolizumab Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject ≥ 18 year ( legal age high ) Chronic AD , present least 2 year visit Eczema Area Severity Index ( EASI ) score ≥12 IGA score ≥ 3 AD involvement ≥ 10 % Body Surface Area ( BSA ) Severe pruritus least 3 last 7 day visit Documented recent history ( within 6 month visit ) inadequate response topical medication Female subject must fulfill one criterion : Female subject nonchildbearing potential Female subject childbearing potential agree true abstinence use effective highly effective method contraception throughout clinical trial 120 day last study drug administration Body weight &lt; 45 kg subject medical history asthma require hospitalization last 12 month screen visit and/or whose asthma wellcontrolled last 3 month screen visit and/or Peak Expiratory Flow ( PEF ) &lt; 80 % predict value Cutaneous bacterial viral infection within 1 week screen visit runin period Infection require treatment oral parenteral antibiotic , antiviral , antiparasitics antifungal within 1 week screen visit runin period Requiring rescue therapy runin period , expect require rescue shortly follow baseline visit Positive serology result ( hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] , hepatitis C antibody Human Immunodeficiency virus [ HIV ] antibody ) screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>